ClinConnect ClinConnect Logo
Search / Trial NCT06410664

Efficiency and Safety of the Prolonged Use of Heat and Moisture Exchangers in ICU

Launched by CHARLES UNIVERSITY, CZECH REPUBLIC · May 10, 2024

Trial Information

Current as of November 08, 2025

Recruiting

Keywords

Pneumonia Heat And Moisture Exchange (Hme) Filter Vap Bundle In Icu Endotracheal Tube Occlusion

ClinConnect Summary

The FILTRex trial is studying the use of special filters called Heat and Moisture Exchangers (HMEs) in patients who are on mechanical ventilation in the Intensive Care Unit (ICU). These filters help to warm and moisten the air that patients breathe, which can be important for their recovery. This trial will compare the effects of using these filters for a longer duration of 72 hours versus the standard 24 hours, to see which is more effective and safe for preventing Ventilator Associated Pneumonia (VAP), a common lung infection in ventilated patients.

To participate in this study, patients need to be at least 18 years old, be in the ICU, and expect to be on mechanical ventilation for at least 72 hours. They should also have a certain score that indicates they are not showing signs of a lung infection at the start of the trial. Participants will have the chance to receive either the longer or standard duration of HME use, and their health will be closely monitored throughout the study. This research aims to improve care for critically ill patients, and your involvement could help make a difference for future patients in similar situations.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Age ≥18 years
  • 2. In-patient in ICU and expected to stay \> 3 days
  • 3. Mechanical ventilation or imminent need of it; predicted length of mechanical ventilation ≥ 72h
  • 4. Clinical Pulmonary Infection score (CPIS) less than six at the baseline 5 No history and symptoms of aspiration at the baseline
  • Exclusion Criteria:
  • 1. Suspected pulmonary infection on admission and in the first 48 hours of mechanical ventilation
  • 2. Pregnancy
  • 3. Acute respiratory distress syndrome
  • 4. Body temperature \< 32°C
  • 5. Airway bleeding or other contraindications for the use of HME
  • 6. An early decision of treatment withdrawal

About Charles University, Czech Republic

Charles University, located in the Czech Republic, is a prestigious institution renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, the university leverages its extensive academic expertise and state-of-the-art facilities to conduct innovative research that aims to improve patient outcomes and contribute to the global medical community. With a focus on ethical standards and rigorous scientific methodologies, Charles University collaborates with various stakeholders to explore new therapies and enhance healthcare practices, fostering a culture of excellence in clinical research.

Locations

Prague, česká Republika, Czechia

Prague, Czechia

Patients applied

0 patients applied

Trial Officials

Kateřina Jiroutková

Principal Investigator

3rd Faculty of Medicine, Charles University and FNKV, Prague

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported